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Abstract
Breast cancer occur both in hereditary and sporadic forms, and the later one comprises an overwhelming majority of breast
cancer cases among women. Numerical and structural alterations involving chromosome 8, with loss of short arm (8p) and
gain of long arm (8q), are frequently observed in breast cancer cells and tissues. In this study, we show that most of the
human breast tumor cell lines examined display an over representation of 8q24, a chromosomal locus RecQL4 is regionally
mapped to, and consequently, a markedly elevated level of RecQL4 expression. An increased RecQL4 mRNA level was also
observed in a majority of clinical breast tumor samples (38/43) examined. shRNA-mediated RecQL4 suppression in MDA-
MB453 breast cancer cells not only significantly inhibit the in vitro clonogenic survival and in vivo tumorigenicity. Further
studies demonstrate that RecQL4 physically interacts with a major survival factor-survivin and its protein level affects
survivin expression. Although loss of RecQL4 function due to gene mutations causally linked to occurrence of human RTS
with features of premature aging and cancer predisposition, our studies provide the evidence that overexpression of
RecQL4 due to gene amplification play a critical role in human breast tumor progression.
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Introduction
Breast cancer is the most leading cause of cancer related deaths
among women [1]. Despite advances in endocrine therapy and
novel targeted agents, metastatic breast cancer still remains an
incurable disease largely because of genetic complexity of this
disease, which confers resistance to many treatment modalities
[2,3]. Breast cancer occurs both in sporadic and hereditary forms.
Sporadic breast cancer comprises a overwhelming majority of
breast tumors, and only 5–10% of cases are hereditary in nature
[4]. Complex karyotypic alterations with potential implications for
breast cancer initiation, progression and metastasis have been
reported in the literature [5,6]. A recent study employing a gene
expression based meta-analysis has identified several chromosomal
regions including gains of 1q41–42, 8q24 and 17q as well as loss of
1p31–21, 8p22–21 and 14q24, etc, that may be causal for breast
cancer metastasis [5,6]. In particular, amplification involving long
arms of chromosome 8 has been frequently reported in multiple
tumors such as osteosarcoma, prostate cancer, pancreatic cancer,
cervical cancer, B-cell acute lymphoblastic leukemia and sacro-
coccygeal teratoma [7–12]. These findings suggest that the
structural alterations of chromosome 8 may play a causal role in
the process of tumor progression. Identification and functional
characterization of potential genes responsible for breast tumor-
igenesis may lead to new therapeutic strategies for effective clinical
management of breast cancer.
Human helicases that share extensive homology with E.coli
RecQ helicase are essential for maintaining genomic stability [13].
Five RecQ helicase members, have been identified in humans.
Mutations in three of which including BLM, WRN and RecQL4
have been linked to distinct human disorders with common
characteristics of premature aging and cancer predisposition[14–
16]. While mutational inactivation of WRN and BLM helicases
leads to Werner (WS) and Bloom syndromes (BS) respectively,
mutations in RecQL4 lead to three autosomal recessive disorders;
Rothmund-Thomson syndrome, Baller-Gerold and RAPADIL-
LINO [16,17]. While the biological functions of BLM and WRN
helicases have been fairly well-established, the similar reports
about RecQL4 have recently begun to emerge. An authentic role
for RecQL4 in the formation of DNA replication initiation
complex has been demonstrated [18]. Furthermore, RecQL4
deficiency in mice leads to growth retardation, early death and
other symptoms similar to human RTS patients [19]. Recent
in vitro studies have shown that RecQL4-deficient fibroblasts
isolated from RTS patients are extremely sensitive to genotoxic
agents [20,21] and that RecQL4 participates in diverse DNA
repair pathways through interaction with multiple DNA repair
proteins [22–24].
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Increased incidence of osteosarcoma has been observed in
RecQL4 deficient RTS patients. On the contrary, elevated
RecQL4 expression has also been reported in human sporadic
osteosarcoma and prostate tumor samples [25,26]. These findings
suggest that RecQL4 can be a double-edged sword whose loss or
gain of expression is crucial for tumorigenic events.
Since over representation of RecQL4 harboring locus 8q24 is
frequently observed in breast cancer cells, we hypothesized that
RecQL4 plays critical roles in breast carcinogenesis. Consistent
with over representation of 8q24, a significantly elevated
expression of RecQL4 was observed in most of the breast cancer
cell lines. An increased RecQL4 mRNA level was also observed in
a majority of clinical breast tumor samples examined. Suppression
of RecQL4 by shRNA dramatically increased the apoptotic
potential of breast cancer cells. Clonogenic cell lines with stable
suppression of RecQL4 displayed a markedly reduced tumorigenic
potential in vivo with an absolute lack of tumor growth in 4 out of
7 nude mice xenografts. Co-immunoprecipitation analysis re-
vealed that RecQL4 physically interacts with a major survival
factor survivin through its C-terminal and helicase domains.
Further, RecQL4 suppression in breast cancer cells reduced the
expression of survivin after oxidative DNA damage. Our study
suggests that RecQL4 probably regulates the survival of breast
cancer cells through its interaction with survivin, and RecQL4
targeting may prove to be effective strategy for breast cancer
treatment.
Results
Genomic Locus of RecQL4 is Amplified in Most of Human
Breast Tumor Cell Lines
To determine the alterations involving the loss of chromosome
8p and gain of 8q, FISH using chromosome 8 specific multicolor
BAND probe was performed on the metaphase spreads of normal
mammary epithelial cells (HMEC) and different breast tumor cell
lines. Primary HMEC cells showed two copies of intact
chromosome 8 but increased copy numbers (from 4 to 8) with
varying 8q lengths (from entire q-arm to distal 1/3 of q) were
observed in almost all of the breast cancer cell lines with the
exception of MDA-MB231 (Fig. 1A). Interestingly, immortalized
non-tumorigenic MCF-10F cell line showed 4 intact copies of
chromosome 8 indicating that the over representation of
chromosome 8 is most likely associated with immortalization
process. Over representation of 8q and under representation of 8p
was most evident in MDA-MB453 breast cancer cell line that
showed 6 copies of chromosome 8q including a pair of
isochromosomes formed by the fusion of two chromosome 8q-
arms. Further, FISH analysis using spectrum orange labeled BAC
(Bacterial Artificial Chromosome) probe proximal to 8q24.3
chromosome locus harboring the RecQL4 gene was performed
in MDA-MB453 and MDA-MB361 cells. Consistent with the
mBAND results, the BAC probe revealed 6 hybridization signals
in MDA-MB453 cells and 4 hybridization signals in MDA-MB361
cells (Fig. 1B).
To verify whether or not increased copies of chromosome 8q
also reflect in the relative enrichment of RecQL4 DNA in breast
cancer cell lines, a primer pair corresponding to RecQL4 exon 4
and intron of exons 4–5 was designed, and quantitative PCR using
genomic DNA as templates was performed. Consistent with
mBAND-FISH data, RecQL4 band intensity and quantitative
real-time PCR result in MDA-MB-231 was very similar to primary
HMEC cells, whereas an enrichment of RecQL4 DNA was
observed in MCF-10F and other four breast tumor cell lines
(MCF-7, MDA-MB361, MDA-MB436 and MDA-MB453 cells,
Fig. 1C). In corroboration with the copy number analysis by
mBAND and quantitative real time PCR analyses, a substantially
increased hybridization intensity was observed only in MCF-10F,
MCF-7, MDA-MB361, MDA-MB436 and MDA-MB453 cells but
not in HMEC normal breast and MDA-MB231 cells (Supple-
mental Fig. 1).
RecQL4 Expression is Upregulated in Human Breast
Tumor Cell Lines and Clinical Breast Tumor Samples
Expression of RecQL4 was next monitored at the protein level
by western blot using the whole cell lysates of normal breast
epithelial cells and cancer cell lines. In corroboration with our
earlier results, RecQL4 protein was substantially elevated in all the
breast cancer cell lines with the exception of MDA-MB231 relative
to primary HMEC cells (Fig. 2A). To verify whether or not
RecQL4 expression is elevated in human breast tumor tissue
samples, RecQL4 mRNA level was examined using TissueScan
Human Breast cancer tissue qPCR array (Origene, Rockville, MD
20850). This array contains cDNA samples of 5 normal breast
tissues and 43 breast tumor tissues with different pathological
grades. As shown in Figure 2B, 88.4% (38/43) of breast cancer
tissues displayed a three-fold higher expression in RecQL4 mRNA
than normal tissue samples. Based on the pathological grades,
72.7% (8/11) of stage I, 92.9% (13/14) of stages IIA-IIB, 92.9%
(13/14) of stages IIIA-IIIB, and 100% (4/4) of stage IV showed a
markedly increased mRNA level of RecQL4. Specifically,
RecQL4 mRNA level was increased by an average 62.5-fold in
metastatic breast tumors. These data suggest that elevated
RecQL4 expression is probably associated with advanced stage
of breast carcinogenesis.
In vitro Clonogenic Survival and in vivo Tumorigenicity
of Breast Tumor Cells by shRNA-mediated RecQL4
Suppression
Elevated level of RecQL4 observed in human breast cancer cells
and tissues prompted us to verify whether RecQL4 is crucial for
breast cancer cell survival and tumorigenesis. Since MDA-MB453
cells showed a classic over-representation of 8q through isochro-
mosomes formation and underrepresentation of 8p, this cell line
was chosen to elucidate the role of RecQL4 in breast carcinogen-
esis. RecQL4 in MD-MBA453 cells was suppressed by a lentiviral-
mediated shRNA approach. Both RecQL4 shRNA and scrambled
control shRNA were procured from Santa Cruz Biotechnology.
Two clones (designated as C5 and C8) with a substantially
decreased level of RecQL4 protein relative to parental and control
shRNA-transduced (ShControl) cells were used for further studies
(Fig. 3A). Clonogenic survival assay was performed on control and
RecQL4 suppressed cell lines. Results presented in Fig. 3B clearly
demonstrated that RecQL4 suppression significantly inhibit the
clonogenic survival when compared to parental and control
ShRNA transduced cell lines. To verify whether or not RecQL4
expression is intimately associated with tumorigenic potential of
breast cancer cells, parental MDA-MB453 and control shRNA
(ShControl) and RecQL4 specific shRNA transduced cells
(ShRecQL4 C5 and C8) were injected subcutaneously into nude
mice. The tumor growth was monitored for 4 weeks. Compared to
mice injected with parental and control shRNA transduced cells,
the tumor size was dramatically reduced in mice injected with
RecQL4 suppressed stable cell lines. Interestingly 4 of 7 mice
injected with RecQL4 suppressed MD-MBA453 cells failed to
show any tumor growth at all (Fig. 3C). These findings clearly
illustrate that RecQL4 expression is critical for the tumorigenic
potential of breast tumor cells.
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RecQL4 Physically Interacts with Survivin
Our preliminary data has found that level of phospho-histone 3
(p-H3) was substantially decreased in RecQL4-suppressed MDA-
MB453 cells. Since survivin has been shown to not only interact
physically with histone H3, but also regulate its phosphorylation
level [27,28], we postulated that RecQL4 may modulate p-H3
level through interaction with survivin. To prove this hypothesis,
we performed Co-IP (immunoprecipitation) to test the association
between RecQL4 and survivin protein using the cell lysates from
U2OS cells expressing either full length of Flag-RecQL4 or Flag-
survivin. Expression of both genes post transfection was confirmed
by Western blotting. When Flag-RecQL4 was precipitated with
anti-Flag antibody, a band corresponding to survivin was detected
with anti-survivin antibody, demonstrating the physical interaction
of RecQL4 with survivin (Fig. 4A). Likewise, endogenous RecQL4
protein was detected in the sample immunoprecipitated with anti-
Flag antibody in U2OS cells expressing Flag-survivin (Fig. 4B). To
Figure 1. Amplification of RecQL4 genomic locus analyzed by mBAND-FISH and quantitative real time PCR. (A) Analysis of
chromosome specific mBAND-FISH in the metaphase spreads of normal primary (HMEC), immortalized (MCF-10F) and tumorigenic breast cancer cell
lines. Chromosomes and chromosome regions positive for the probe are shown in the inserts. (B) FISH analysis using spectrum orange labeled BAC
(Bacterial Artificial Chromosome) probe proximal to 8q24.3 chromosome locus harboring the RecQL4 gene in MDA-MB453 and MDA-MB361 cells. The
BAC probe was purchased from Open Biosystems (RP11–374B7, Huntsville, Alabama, USA). (C) Upper panel: Agarose gel electrophoresis showing the
abundance of RecQL4 genomic DNA detected by PCR in breast cancer cell lines relative to normal primary and immortalized breast epithelial cells.
GAPDH was used as an internal control; Lower panel: Abundance of RecQL4 genomic DNA detected by quantitative real time PCR in breast cancer
cell lines relative to normal primary and immortalized breast epithelial cells. GAPDH was used for normalizing the values of RecQL4.
doi:10.1371/journal.pone.0069600.g001
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determine which of the RecQL4 functional domains interacts with
survivin, various Flag-RecQL4 constructs with deletion of N-
terminal (NT, 1–475 aa), helicase domain (HD, 476–824aa) or C-
terminal (CT, 825–1208aa) were generated and designated as
Flag-RecQL4NT(2), Flag-RecQL4HD(2), and Flag-
RecQL4CT(2), respectively (Fig. 4C, upper panel). Each of these
truncated RecQL4 constructs was co-expressed with survivin
(without Flag tag) in 293 cells and immunoprecipitated with anti-
Flag antibody. A similar expression level of truncated RecQL4 was
revealed in transfected cells by Western blot analysis. While N-
terminal deletion did not affect the interaction between RecQL4
and survivin, deletion of either HD or CT domain of RecQL4
disrupted its interaction with survivin (Fig. 4C, lower panel). These
findings indicate that interaction of RecQL4 with survivin is
mediated by HD and CT domains.
RecQL4 suppression leads to a decreased basal and
induced level of survivin. Observation of physical interaction
between RecQL4 and survivin prompted us to verify whether or
not RecQL4 suppression affects survivin expression. In MDA-
MB453 cells, RecQL4 suppression reduced the basal level of
survivin relative to parental and control shRNA transduced cells
(Fig. 5A). The dependence of survivin expression on RecQL4
became more evident when the cells were exposed to hydrogen
peroxide (H2O2). Survivin expression in parental MDA-MB453
cells was greatly induced at 1 h and 1.5 h post H2O2 treatment,
whereas in RecQL4-suppressed cells, survivin induction was
substantially inhibited. In addition, phosphorylation of histone
H3 (H3ser10), one of the well-known survivin-interacting proteins
[29], also showed a much reduced level in RecQL4 suppressed
cells (Fig. 5A). We then tested whether or not survivin expression
can be induced in RecQL4-silenced MDA-MB453 cells by
transiently transfection of either pFlag-CMV4 or pFlag-CMV4-
RecQL4 expression vectors. Western blot result revealed an
increased level of survivin expression at 48 h post RecQL4
transfection (Fig. 5B).
Discussion
Cancer metastasis is believed to progress in a multi-step fashion
resulting from accumulated gene mutations and amplifications.
Among various chromosomal aberrations related to cancer
metastasis, chromosomal 8q24 region has been reported to be a
frequent site of somatic amplification in a variety of human
cancers including breast [6,30]. Gains of 8q have previously been
detected in 50% of the primary breast tumors examined by
Comparative genomic hybridization, and have been found to be
related to invasive and metastatic potential of breast tumors [31].
By ranking the relation of chromosomal regions to metastasis in a
large dataset of more than 1200 breast tumors, RecQL4 at 8q24
has been identified as one of the potential metastasis promoting
genes [32]. However, the precise role of RecQL4 in breast
tumorigenesis is not entirely known. In this study, we showed Chr.
8q gains and concomitantly, a highly elevated level of RecQL4
protein in breast tumor cell lines. Moreover, a markedly increased
mRNA level of RecQL4 was identified in breast tumor tissues with
the expression being the highest in metastatic tumor samples. This
finding suggests the possibility that RecQL4 may be of use as a
prognostic marker for advanced stage of breast cancer.
Unlimited replicative potential and resistance to apoptosis are
the hallmarks of human malignancies [33]. In normal cells,
accumulation of mutations is prevented through selective elimi-
nation of heavily damaged cells by apoptotic death, which is
regulated by highly coordinated signal transduction pathways that
regulate cell cycle checkpoint and DNA repair activities [34,35].
Deregulation of these pathways enables the cells to proliferate
infinitely through evasion of apoptosis so that cells can tolerate
additional gene mutations that are necessary for malignant
transformation [36,37]. Recent studies have shown that RecQL4
plays an authentic role in DNA replisome assembly at DNA
replication origin sites [18,38]. Further, requirement of RecQL4
has been demonstrated for the assembly of Cdc45-MCM2-7-
GINS complex in human cells [39,40]. In the light of these
observations, there is a strong possibility that RecQL4 through its
elevated expression contributes to infinite replicative potential of
breast cancer cells. In support, we demonstrated that RecQL4
suppression led to reduced proliferation potential of MDA-MB453
cells. In addition to proliferation inhibition, RecQL4 suppression
also greatly reduced the tumorigenic potential of breast cancer
cells in vivo. An absolute lack of tumor growth in 4 of 7 mice
injected with RecQL4-suppressed breast cancer cells strongly
suggests that RecQL4 expression is intrinsically associated with
breast cancer cell growth and tumor progression. Association of
RecQL4 elevated expression with prostate [26] and breast
carcinogenesis indicates the possibility that RecQL4 may be a
major replicative helicase for cancer cells.
Genomic instability is thought to play a major role in premature
aging and cancer development processes [33]. Three of the human
RecQ helicase disorders with mutations in WRN, BLM and
RecQL4 helicases exhibit premature aging and cancer suscepti-
bility owing to perturbations in DNA replication, transcription,
Figure 2. RecQL4 protein or mRNA level in breast tumor cell
lines and clinical breast cancer specimens. (A) Western blot
detection of RecQL4 protein level in HMEC, MCF-10F and five breast
tumor cell lines. b-Actin was used to verify equal loading of proteins. (B)
Analysis of RecQL4 expression by quantitative real time PCR in normal
breast tissues and breast cancer specimens with different pathological
grades. TissueScan breast cancer tissue qPCR array was purchased from
Origene. RecQL4 expression detected in normal breast tissues was
considered as 1. The data represent mean 6 SD from three
independent experiments.
doi:10.1371/journal.pone.0069600.g002
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recombination and repair [41]. RecQL4 deficient RTS displays
heterogeneous clinical profiles with common features of premature
aging and the early development of cancers, in particular
osteosarcomas [42]. In corroboration with pathological symptoms,
somatic cells isolated from RTS patients also displayed retarded
proliferation and an enhanced sensitivity to agents of oxidative
stress and DNA replication blockage [20,21]. Moreover, RecQL4-
deficient cells show genomic instability, including trisomy,
aneuploidy and chromosomal rearrangements [43]. These results
illustrate the importance of RecQL4 for maintenance of genomic
stability in normal cells. In this study, we have demonstrated that
shRNA-mediated RecQL4 suppression in breast cancer cells not
only inhibits their in vitro clonogenic survival and in vivo tumori-
genicity, but also sensitizes them to apoptotic induction. While loss
of RecQL4 in RTS patients leads to osteosarcoma due to
compromised DNA metabolic activities [16], gain of expression
may favor cancer cell growth and survival through up regulation of
DNA replication and repair capabilities. We observed that
RecQL4 is most highly expressed in metastatic breast tumors,
together with our previous findings in prostate tumors [26]
suggests that elevated expression of RecQL4 is potentially
significant for metastatic progression of the disease. Thus, RecQL4
may serve as a double-edged sword whose loss or gain of
expression is associated with human tumor progression.
Based on our previous report [26], Rb and E2F proteins
physically interact with RecQL4 promoter, and Rb hyperpho-
sphorylation correlates with RecQL4 expression in prostate tumor
cell lines which is further supported by the data that abolition of
Rb hyperphosphorylation by histone deacetylase inhibitor Tri-
chostatin A (TSA) treatment reduced the expression of both E2F1
and RecQL4. Thus, both amplification of RecQL4 genomic locus
and the transcriptional mechanism(s) probably contribute to the
up-regulation of RecQL4 expression in human cancer cells.
Demonstration of a physical interaction, for the first time in this
study, between RecQL4 and survivin indicates the potential
importance of RecQL4 in carcinogenic process. Survivin is a
unique inhibitor of apoptosis usually expressed in the embryonic
lung and fetal organs during the developmental stages but
undetectable in most of normal adult tissues [44,45]. However,
selective expression of survivin has been demonstrated in both
Figure 3. In vitro clonogenic survival and in vivo tumorigenic assays in MDA-MB453 tumor cells after knock-down of RecQL4
expression. (A) Western blot analysis of RecQL4 expression in parental, control shRNA (ShControl) and RecQL4 specific shRNA transduced MDA-
MB453 cells (ShRecQL4-C5 & C8). RecQL4 expression was highly reduced in ShRecQL4-C5 and C8 stably selected by puromycin antibiotics. (B)
Clonogenic survival assay was performed on ShRecQL4-C5 and C8 cells relative to parental and ShControl cells. Data presented at each time point
were the mean value of eight cultures from two independent experiments. Bars indicate mean6SD. (C) Analysis of in vivo tumorigenicity of MDA-
MB453 cells after RecQL4 silencing. Parental, ShControl and ShRecQL4-C5 & C8 cells were subcutaneously injected into seven immunosuppressed
nude mice and tumor growth was monitored for 4 weeks. Tumor growth as a function of time is shown in the left panel. Images of tumors resected
from mice are shown in the right panel. Note that 4 of 7 mice injected with either ShRecQL4-C5 or C8 cells did not show any tumor growth. Bars
indicate mean6SD.
doi:10.1371/journal.pone.0069600.g003
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transformed cells and most human cancers [46,47]. In addition to
apoptosis inhibition, survivin also regulates mitotic spindle
checkpoint, and promotes angiogenesis [48]. In this study, we
have shown that RecQL4 not only interacts with survivin through
HD and CT domains but also seems to regulate survivin
expression in the absence and presence of exogenous DNA
damage. Although the precise mode of survivin regulation by
RecQL4 awaits further studies, our finding suggests that RecQL4
probable protects the breast cancer cells from DNA damage-
induced apoptosis through upregulation of survivin.
The multifaceted roles of RecQL4 in diverse DNA metabolic
activities have been steadily emerging in recent times [23]. In this
study, we have demonstrated that RecQL4 elevated expression
confers proliferation advantage and survival to breast cancer cells.
The highest level of RecQL4 expression observed in metastatic
prostate [26] and breast cancer cells points out a potential
prognostic significance of RecQL4 for advanced stages of breast
and prostate cancers. Suppression of RecQL4 not only affected the
proliferation but also abolished the tumorigenic potential of breast
cancer cells. Additionally, RecQL4 through its interaction with
survivin seems to be a key factor for determining the fate of breast
cancer cells after DNA damage. These novel properties make
RecQL4 as an ideal targeting molecule for improving the
efficiency of breast cancer treatment. More specifically,
Figure 4. RecQL4 associates with survivin. (A) Endogenous survivin was immunoprecipitated with Flag-RecQL4 recognized by an anti-Flag
antibody from cell extracts of 106 U2OS cells, but not with Flag-GFP. The immunoprecipitated proteins were detected with antibody against survivin
(Cell Signal). Five percent of the lysate was used for the loading control (Input) and the remaining 95% for co-immunoprecipitation. (B) Endogeneous
RecQL4 was immunoprecipitated with Flag-survivin recognized by an anti-Flag antibody from cell extracts of 106 U2OS cells, but not with Flag-GFP.
The immunoprecipitated proteins were visualized by Western blot analysis with antibody against RecQL4 (Cell signal). (C) In the upper panel,
schematic diagram of RecQL4 deletion constructs used for Co-IP studies is shown. In the lower panel, 293T cells were co-transfected with pRc-CMV2-
survivin and one of the Flag-tagged truncated RecQL4 expressing vectors: pFlag-RecQL4-NT(2), pFlag-RecQL4-HD(2) or pFlag-RecQL4-CT(2).
Survivin was immunoprecipitated with N-terminal (NT) deleted Flag-RecQL4 protein, not with helicase domain (HD) or C-terminal (CT) deleted Flag-
RecQL4 protein.
doi:10.1371/journal.pone.0069600.g004
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RecQL4-survivin pathway provides a potential target for the
development of new diagnostic and treatment modalities for breast
cancer patients.
Materials and Methods
Cell Culture and Reagents
Human breast tumor cell lines (MCF-7, MDA-MB231, MDA-
MB361, MD-MBA436 MDA-MB453) were purchased from
ATCC (American Type Culture Collection, USA). Cells were
cultured in PRMI 1640 medium containing 10% FBS and
antibiotics. Primary human mammary epithelial (HMEC) cells
were purchased from Invitrogen and cultured in HuMEC serum-
free medium (Invitrogen). MCF-10F cells were maintained in
DMEM/F12 medium supplemented with 5% horse serum and
growth factors (insulin, hydrocortisone and EGF). Antibodies for
human RecQL4, survivin, phospho-H3 and total H3 were
purchased from Cell Signaling Technology, Boston, MA, USA.
Plasmid Construction
Full-length human RecQL4 cDNA was obtained from Geneco-
poeia and subcloned into NotI/XbaI sites of pFlag-CMV4 vector
(Sigma) at NotI/XbaI sites. To generate a series of truncated
versions of RecQL4, RecQL4 cDNA fragments with 1-824aa (C-
terminal deletion) and 476-1208aa (N-terminal deletion) were
PCR amplified and cloned into NotI/XbaI sites of pFLAG-CMV4
vector, and were designated as RecQL4-CT(2) and
RecQL4NT(2), respectively. For RecQL4 helicase domain
(HD)-deleted vector, NT fragment (1-475aa) was first PCR-
amplified and cloned into NotI/EcoRI sites of pFlag-CMV4, then
CT fragment (825-1208aa) was PCR-amplified and in-frame
cloned into EcoRI/XbaI sites to form RecQL4HD(2) vector with
deletion of HD domain. All constructs were verified by sequencing
and expected sizes of proteins were confirmed by western blot.
The survivin cDNA clone was ordered from Open Biosystems.
The survivin cDNA was then PCR amplified and cloned into
HindIII-XbaI digested pFlag-CMV4 vector using the following
primer set: P1:ACCAAGCTTATGGGAGCTCCGGCG CTG,
P2:GCTCTAGATCAGTCCTTATTCTCAATC.
Plasmid Transfection
The transfection was performed using Lipofectamine reagents
(Invitrogen, USA) following the recommended procedure. For
transfection in 35 mm dishes, 2 mg of DNA (plasmid) and 8 ml of
Plus reagent were diluted in 250 ml serum-free DMEM basal
medium, mixed and incubated at room temperature for 15 min.
In a separate tube, 12 ml Lipofectamine was diluted in 250 ml
serum-free DMEM basal medium, combined with DNA-Plus
solution, and incubated at room temperature for additional
15 min. Cells in exponential growth phase with 70–80%
confluency in 35 mm dishes were washed once with serum-free
medium, and incubated with 2 ml serum-free medium plus
Lipofectamine-DNA complexes at 37uC in a humidified incubator
for 3h. Then, 2.5 ml medium with 20% FBS was added and the
transfection mixture was replaced with complete culture medium
after 18–24 h of transfection. MDA-MB453 cells show a high
potency for transfection and more than 90% of the cells were
observed to be EGFP-positive after transfection with EGFP-
expressing vector.
In situ Fluorescence Hybridization and Chromosome 8
mBAND Analysis
Exponentially growing cells were treated with 0.1 mg/ml
Daemecolcine (Sigma) at 37uC for 6–8 hours. Chromosome
preparations were made following a standard procedure. For
FISH analysis, spectrum orange labeled BAC (Bacterial Artificial
Chromosome) probe proximal to 8q24.3 chromosome locus
harboring the RecQL4 gene was purchased from Open Biosys-
tems (RP11-374B7, Huntsville, Alabama, USA). For mBAND-
FISH analysis, multiple fluorescent DNA probe for chromosome 8
was purchased from Metasystems (Waltham, MA, USA). In brief,
slides were washed with 16PBS twice, incubated with 0.005%
pepsin at 37uC for 2 minute, followed by fixation in formaldehyde
(3%) for 10 minutes. After washing in 16PBS, 10–15 ml of the
probe was placed on each slide, denatured at 80uC for 3 minutes,
and then incubated in a humid environment at 37uC for 2–4 days.
After hybridization, the slides were incubated in 16SSC at 75uC
for 5 minutes followed by three washes of 3 min each in 46SSC/
0.05% Tween 20. After rinsing in PBS, the slides were mounted
Figure 5. RecQL4 modulates survivin expression. (A)Western blot analysis showed a reduced level of survivin expression and phospho-histone
3 (p-H3) in RecQL4 suppressed cells (ShRecQL4-C5 and C8) at 1 and 1.5 h post 0.25 mM H2O2 treatment. Bax protein did not show any alteration
after oxidative DNA damage. b-Actin was used to verify equal loading of proteins. (B) Forced expression of RecQL4 in ShRecQL4-C5 and C8 cells led to
an increased level of survivin expression at 48 h post transfection with pFlag-RecQL4 plasmid (lane 1) or plasmids (lane 2 & 3) containing nucleotide
substitution at RecQL4 ShRNA-targeted area without changing the amino acid sequence.
doi:10.1371/journal.pone.0069600.g005
RecQL4 Amplification in Breast Tumorigenesis
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e69600
with coverslips using an anti-fade solution containing 200 ng/ml
of DAPI. The images were captured and analyzed using Zeiss
fluorescence microscope using the Metasystem ISIS software. A
total of 10–15 metaphases were analyzed for each cell line.
Quantitative Real Time RT-PCR
Abundance of RecQL4 genomic locus in normal and breast
cancer cells was analyzed by quantitative real-time PCR (Applied
Biosystems 7300) using SYBR Green PCR master mix and a pair
of primers corresponding to RecQL4 exon 4 and intron of exons
4–5. The primer sequences are P1-TACGGCTCAACATGAAG-
CAG and P2-CCACATAGGAGGGTCACTGG with expected
PCR product size of 117 bp. Quantitative real-time PCR was
done in 25 ml reaction volume including100 ng DNA template,
1.5 ml RecQL4 primer set (10pmol/ml) or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, 5pmol/ml) with annealing
temperature of 60uC for 30sec. The genomic primer sequences for
GAPDH are P1-CGGCTACTAGCGGTTTTACG and P2-
AAGAAGATGCGGCTGACTGT with PCR product of 159bp.
GAPDH level was used as an internal reference gene to normalize
the level of DNA template. For real time RT-PCR, the primer pair
for RecQL4 is: P1-TCACAGT GAGGTCCCAGATT and P2-
CTGACTTCTTGGAAGGCTGA with PCR product of 156 bp.
b-actin was used as the internal control for normalization of
RecQL4 mRNA. The primer sequences forb-actin are: P1-
CAGCCATGTACGTTGCTAT CCAGG and P2-AGGTCCA-
GACGCAGGATGGCATG (Origene). Relative RecQL4 geno-
mic copy number or mRNA level was quantified from the
comparative threshold cycle (CT) method as described previously
[49].
Co-IP (coimmunoprecipitation) Assay
For Co-IP, cellular proteins were solubilized in lysis buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM
EDTA, 5 mM EGTA, 20 mM NaF, 0.1 mM PMSF, 0.5 mM
benzamidine, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 2 mM micro-
cystin and 0.1 mM NaVO3). Total lysates were incubated with
Anti-Flag-M2 magnetic beads (Sigma-Aldrich, St. Louis, MO,
USA) at 4uC for 2 h. The beads were washed several times to get
rid of aspecific binding of proteins. The beads were finally heated
at 80uC in Laemmli buffer and immunoprecipitated proteins were
detected by SDS/PAGE and Western blotting using antibodies
specific for RecQL4 and survivin.
shRNA Lentiviral Particles
Human control and RecQL4 specific ShRNA lentiviral particles
were procured from Santa Cruz. Cells were transduced with
lentiviral particle in the presence of 5 mg/ml polybrene according
to the manufacturer’s instructions.
Clonogenic Survival and Tumorigenicity of RecQL4-
Suppressed Breast Cancer Cells
The clonogenic survival assay for parental, control and RecQL4
shRNA transduced (clones C5 and C8) MDA-MB453 cells were
performed by plating 16104 cells in 30 mm dishes. Cell number
was determined at 24 h interval for 5 days for each cell line using
Coulter counter. Data presented at each time point were the mean
value of eight cultures from two independent experiments.
Xenograft assay in immunodeficient nude mice was performed
essentially as described before [26,50]. To determine whether
RecQL4 suppression leads to reduced tumorigenicity in vivo, 66106
cells from each of the four cell lines [parental MDA-MB453,
empty vector–transfected cells, and two RecQL4 shRNA–trans-
fected clones (C5 and C8)] were injected subcutaneously into nude
mice. Seven mice were used for each treatment. Mice were housed
in SPF (specific pathogen free) animal facility, and anesthetized by
1% isoflurane through inhalation before tumor cell injection.
Animals were monitored at least two times per week or daily when
the mice began showing tumors or decreased activity. In addition,
animals were weighted at least three times per week for monitoring
their overall health. The tumors were measured using calipers and
the tumor size was recorded. The mice will be euthanized if any
animals were found unexpectedly to be moribund, rapid body
weight loss (over 20% of base line of body weight), hunched
posture, lethargy or persistent recumbency, jaundice and/or
anemia, or a tumor estimated to be over 10% of the body weight.
If the animals display no obvious sign of morbidity, mice will be
maintained for up to 4 weeks, then euthanized and processed for
tumor analysis. The entire experimental animal protocol and
procedure were approved by the Animal Care & Welfare
Committee of the Beijing Institute of Genomics (Approved
Document Number: 2012A004).
Supporting Information
Figure S1 Amplification of RecQL4 genomic locus
analyzed by Southern blot analysis. 20 mg of genomic
DNA isolated from each of the cell line was digested with 25 U
NcoI for 6 h and separated on 0.8% agarose gel by electrophoresis
at 40 V for 8 h in TAE buffer. After denaturation and
neutralization, the DNA was transferred onto Nylon membrane
in 106SSC buffer and cross-linked with 254 nm UV at 0.125 J/
cm2. The membrane was pre-hybridized in 12 mL of Rapid-
hybrid buffer (GE, Rapid-hyb Buffer, RPN1635) at 65uC in a
rotator for 2 h and then hybridized with 32P-dCTP-labeled probe
1 and probe 2(Takara, Random Primer DNA Labeling Kit,
D6045) at 65uC overnight. The membrane was washed with
26SSC, 16SSC and 0.16SSC with 0.1% SDS for 20 min, and
then exposed to Kodak film at 280uC for 8 h. The hybridization
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